CVS Health Corporation
CVS Health Corporation (CVS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cvs · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CVS Health Corporation (CVS) measures how much investors pay for each dollar of the company's trailing earnings. CVS's current PE ratio of 42.13x is calculated by dividing its stock price of $96.92 by its TTM earnings per share of $2.30. +66.3% elevated vs 5Y avg 25.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%15.9x
MedianQ3 · 75%56.9x
Max
At 42.13x, CVS's current P/E is higher than in 95% of its annual fiscal year readings over the past 19 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Healthcare Plans · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CVS Health CorporationYou CVS | $123.7B | 42.13x | +145.6% | $2.30 |
 Bristol-Myers Squibb Company BMY | $114.1B | 15.61x | -9.0% | $3.46 |
 Cigna Corporation CI | $76.4B | 12.29x | -28.4% | $22.40 |
 Cencora, Inc. COR | $53.3B | 38.98x | +127.2% | $8.02 |
 Elevance Health Inc. ELV | $90.3B | 13.73x | -20.0% | $25.53 |
 GSK plc GSK | $101.7B | 6.45x | -62.4% | $5.64 |
 HCA Healthcare, Inc. HCA | $79.6B | 15.88x | -7.4% | $29.40 |
Industry Average 6 peers with valid PE | — | 17.15x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 56.87x | $1.40 | +364.3% | |
2024-12-31 FY2024 | 12.25x | $3.66 | +0.7% | |
2023-12-31 FY2023 | 12.16x | $6.49 | -57.1% | |
2022-12-31 FY2022 | 28.36x | $3.29 | +66.8% | |
2021-12-31 FY2021 | 17.01x | $6.07 | +36.6% | |
2020-12-31 FY2020 | 12.45x | $5.48 | -14.5% | |
2019-12-31 FY2019 | 14.57x | $5.10 | — | |
2018-12-31 FY2018 | — | $-0.57 | — | |
2017-12-31 FY2017 | 11.17x | $6.49 | -29.9% | |
2016-12-31 FY2016 | 15.92x | $4.96 | -23.7% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CVS Health Corporation (CVS) measures how much investors pay for each dollar of the company's trailing earnings. CVS's current PE ratio of 42.13x is calculated by dividing its stock price of $96.92 by its TTM earnings per share of $2.30.
Frequently asked questions
CVS pe ratio · 6 questionsCVS's current PE ratio is 42.13x as of 2026-06-08, based on a stock price of $96.92 and TTM EPS of $2.30. Data sourced from Financial Modeling Prep via CVS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CVS Health Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08